Armata Pharmaceuticals Inc (NYSE American: ARMP), a clinical-stage biotechnology company, announced yesterday that the earlier announced merger between C3J Therapeutics Inc and AmpliPhi Biosciences Corporation (NYSE American: APHB) has been completed.

The new integrated company is named Armata Pharmaceuticals Inc and it will concentrate on the development and advancement of phage-based therapeutic candidates to treat antibiotic-resistant infections. Armata will trade on the NYSE American stock exchange under the symbol 'ARMP.'

Concurrent with the closing of the merger, an investor syndicate comprised of certain existing C3J shareholders invested USD10m into Armata, bringing the company's cash balance to approximately USD16m. The financing proceeds, together with cash on hand, will be used to advance the combined company's preclinical and clinical programs and for other corporate and general purposes.

LifeSci Capital acted as the exclusive financial advisor to C3J and Thompson Hine LLP served as legal counsel. Ladenburg Thalmann & Co Inc acted as exclusive financial advisor to AmpliPhi and Cooley LLP acted as legal counsel.